AGT and cardiac hypertrophy: Sacubitril/valsartan prevented myocardial fibrosis and remodelling and improved cardiac function after myocardial infarction in mice [28] and rats [29,30], and in streptozotocin-induced diabetic hearts in mice [31]; it reduced cardiomyocyte size in Ang II-induced cardiac hypertrophy in mice [32], attenuated LV fibrosis and dysfunction in high-salt diet-induced diastolic dysfunction in rats [33], and reduced BP and prevented stroke in stroke-prone hypertensive rats [34].